<DOC>
	<DOCNO>NCT00843947</DOCNO>
	<brief_summary>This Phase II trial design evaluate efficacy toxicity RIST , condition fludarabine busulfan , use G-CSF mobilized PBSC HLA-matched sibling unrelated volunteer donor . The primary endpoint study day 100 TRM ( Treatment Related Mortality ) . Secondary endpoint include response , engraftment time , acute chronic GVHD , chimerism , toxicity , progression-free survival overall survival . Objectives - To assess efficacy toxicity Reduced Intensity Transplant ( RIST ) patient hematological malignancy , condition fludarabine ( Fludara® ) busulfan intravenous ( Busulfex™ ) . - To evaluate progression-free survival overall survival . - To determine donor chimerism . - To assess risk acute chronic graft versus host disease ( GVHD ) .</brief_summary>
	<brief_title>Reduced Intensity Stem Cell Transplantation ( RIST ) Patients With Hematological Malignancies Conditioned With Fludarabine Busulfan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>• Diagnosed ( follow ) Disease Subtype Disease Status Leukemia Acute myelogenous leukemia ( AML ) Recurrent disease remission* OR CR1 poorrisk cytogenetics , antecedent hematological disease ( i.e . myelodysplasia ) treatmentrelated leukemia Acute lymphoblastic leukemia ( ALL ) Recurrent disease remission* OR CR1 Philadelphia chromosome poor risk cytogenetics Chronic myelogenous leukemia ( CML ) First second chronic phase . There must document disease progression imatinib mesylate ( Gleevec ) therapy OR document lack cytogenetic response 6 month postimatinib initiation OR imatinib intolerance . Patient Inclusion criterion ( Continued ) Chronic lymphocytic leukemia ( CLL ) Recurrent disease fludarabinebased therapy . Patients must chemosensitive** disease time relapse . Lymphoma Recurrent Hodgkin 's Lymphoma Recurrent NonHodgkin 's lymphoma ( NHL ) ( Low , intermediate high grade ) Transformed NHL Patients must prior autologous transplantation receive cytoreductive therapy time relapse achieve complete remission ( CR ) CR/unconfirmed ( CRu ) define International Workshop OR Patient relapse disease require &gt; 2 salvage regimen achieve CR CRu . Multiple Myeloma Recurrent Myeloma Patients must prior autologous transplantation demonstrate chemosensitivity** time relapse Myelodysplastic Syndrome # RA/RARS RCMD/RCMDRS RAEB1 Patients must transfusiondependent International prostate symptom score ( IPSS ) 1.5 high Advanced myeloproliferative disease Myelofibrosis myeloid metaplasia ; primary evolve MPD Patient must transfusion dependent evidence progressive organomegaly evidence myelodysplasia remission define morphological remission bone marrow aspirate/biopsy show &lt; = 5 % blast within 4 week start therapy . ( Cytogenetic molecular remission require ) In CLL , chemosensitivity define great 50 % reduction wbc lymphadenopathy . In MM , define great 50 % reduction Mcomponent plasmacell marrow infiltration . base WHO classification system . Patients RAEB2 del ( 5q ) exclude 56/6 HLAmatched sibling 910/10 match unrelated donor Age &gt; 50 OR age 1850 , preexist medical condition , receive prior therapy ( i.e . prior ) autologous transplantation ) consider high risk conventional myeloablative transplantation • Karnofsky performance status le 50 % Positive pregnancy test , inability unable pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy Corrected pulmonarydiffusing capacity le 35 % A cardiac ejection fraction le 30 % A serologic evidence infection human immunodeficiency virus Inability give inform consent Psychiatric illness mental deficiency make compliance treatment inform consent impossible Decompensated liver disease serum bilirubin &gt; 2.0 mg/dl Serum creatinine &gt; 2.0 mg/dl Uncontrolled active infection Uncontrolled CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>